SS
APRE icon

SBI Securities’s Aprea Therapeutics APRE Stock Holding History

SBI Securities’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12 Buy
16
+1
+7% +$1 ﹤0.01% 3823
2025
Q4 		$13 Sell
15
-27
-64% -$33 ﹤0.01% 3840
2025
Q3 		$62 Buy
42
+2
+5% +$3 ﹤0.01% 3647
2025
Q2 		$68 Hold
40
– – ﹤0.01% 3648
2025
Q1 		$82 Hold
40
– – ﹤0.01% 3507
2024
Q4 		$132 Buy
+40
New +$134 ﹤0.01% 3379

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SBI Securities's APRE Position: Q1 2026 in Review

SBI Securities increased its Aprea Therapeutics (APRE) stake by 6.7% in Q1 2026, buying an estimated $1 and bringing the position to 16 shares worth $12. The position accounts for ﹤0.01% of the portfolio, ranked #3823.

SBI Securities first reported a position in APRE in Q4 2024 and has held it in 6 quarters since. The position peaked at $132 in Q4 2024. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

  • SBI Securities held 16 shares of Aprea Therapeutics worth $12 as of Q1 2026.
  • SBI Securities bought 1 Aprea Therapeutics share in Q1 2026, an estimated $1.
  • Aprea Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3823 holding.
  • SBI Securities first reported a position in Aprea Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Aprea Therapeutics position peaked at $132 in Q4 2024.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.